세계의 암 분자진단 시장 : 암 유형별, 제품 유형별, 장소별 예측 및 주요 컨설턴트 가이드, 인공지능(AI)의 영향(2026-2030년)

Report Overview:

Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 140 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like ......

• personalized medicine
• pharmacogenomics
• liquid biopsy
• minimal residual disease testing
• emergence of new economies with large markets
• physician diagnostics being displaced by new intelligent diagnostic tests

Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base.

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Table of Contents

1. Market Guides

• 1.1. Cancer MDx - Strategic Situation Analysis
• 1.2. Guide for Executives, Marketing, and Business Development Staff
• 1.3. Guide for Management Consultants and Investment Advisors
• 1.4. Impact of Artificial Intelligence on Cancer MDx

2. Introduction and Market Definition

• 2.1. What are Molecular Diagnostics?
• 2.2. The Diagnostics Revolution
• 2.3. Market Definition
  • 2.3.1. Revenue Market Size
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare Spending
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Healthcare and Pharmaceuticals
  • 2.5.3. Spending on Diagnostics
  • 2.5.4. Important Role of Insurance for Medical Services

3. Market Overview

• 3.1. Market Segments
  • 3.1.1. Traditional Market Segmentation
  • 3.1.2. Laboratory Focus and Segmentation
• 3.2. Industry Structure
  • 3.2.1. Hospital Testing Share
  • 3.2.2. Economies of Scale
  • 3.2.3. Physician Office Lab's
  • 3.2.4. Physician's and POCT

4. Market Trends

• 4.1. Factors Driving Growth
  • 4.1.1. New Diagnostics Create New Markets
  • 4.1.2. New Roles for Diagnostics
  • 4.1.3. Aging Effect
  • 4.1.4. Expanding the Pharmaceutical Toolbox
  • 4.1.5. Regulatory Retreat
• 4.2. Factors Limiting Growth
  • 4.2.1. Falling Prices
  • 4.2.2. Lower Costs
  • 4.2.3. Wellness has a Downside
• 4.3. Instrumentation, Automation and Diagnostic Trends
  • 4.3.1. Traditional Automation and Centralization
  • 4.3.2. The New Automation, Decentralization and Point Of Care
  • 4.3.3. Instruments Key to Market Share
  • 4.3.4. Bioinformatics Plays a Role
  • 4.3.5. PCR Takes Command
  • 4.3.6. Next Generation Sequencing Fuels a Revolution
  • 4.3.7. NGS Impact on Pricing
  • 4.3.8. Whole Genome Sequencing, A Brave New World
  • 4.3.9. Companion Diagnostics Blurs Diagnosis and Treatment
  • 4.3.10. Shifting Role of Diagnostics
  • 4.3.11. Multiplexing and Foundation One
  • 4.3.12. Pharmacogenomics Technology
  • 4.3.13. Gene Editing and Gene Therapy

5. Molecular Diagnostics Recent Developments

• 5.1. Recent Developments - Importance and How to Use This Section
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. Biodesix Revenues up
• 5.3. Waters to buy Becton unit
• 5.4. QuidelOrtho refocuses with LEX acquisition
• 5.5. Guardant Health Guardant360 Tissue
• 5.6. AccuStem Sciences & EmeritusDx partner for Lung Cancer Screening
• 5.7. LetsGetChecked LaunchesHereditary Cancer Test
• 5.8. Guardant Health's Colorectal Test New Status
• 5.9. Tempus xT CDx
• 5.10. OneCell Diagnostics Raises $16M
• 5.11. A. Menarini to use Nucleix Bladder Cancer Test
• 5.12. Foundation Medicine, Repare Therapeutics to Develop CDx
• 5.13. NHS Declines to Accelerate Grail Galleri Implementation
• 5.14. GeneDx Sees Growing Demand for Testing
• 5.15. Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
• 5.16. ClearNote Health Expands Into Immunotherapy Monitoring
• 5.17. Foundation Medicine to Collaborate on CDx for Lung Cancer
• 5.18. Qiagen and Myriad Genetics Partner to Develop Cancer CDx
• 5.19. Lung Cancer Data Heralds Shift for Hummingbird Dx
• 5.20. PamGene Awarded Euro-7.5M for Immunotherapy Test
• 5.21. Grail Cancer Test Faces New Clinical Questions
• 5.22. Freenome Acquires Cancer Dx Firm Oncimmune
• 5.23. Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology
• 5.24. Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients
• 5.25. Digital Pathology Meets Cancer Sequencing
• 5.26. Exact Sciences Preps Expanded Oncology Portfolio
• 5.27. Qiagen Details Oncology Plans for Digital PCR Platform
• 5.28. Sema4 Exiting Reproductive Health Screening
• 5.29. Thermo Fisher Introduces Cancer Profiling Assay
• 5.30. Genomic Test IDs Cysts Likely to Progress to Cancer
• 5.31. Naveris to Commercialize Virus-Related Cancer Tests
• 5.32. Larger Liquid Biopsy Panels Loom
• 5.33. Halo Diagnostics to Offer Genomic Profiling Tests
• 5.34. BillionToOne Raises $125M
• 5.35. Local Cancer Genomic Profiling Options Grow
• 5.36. German MDx Firm Mainz Biomed Raises $10M in IPO
• 5.37. Guardant Health Q3 Revenues Up 27 Percent
• 5.38. BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection
• 5.39. Nucleix to Invest in Early-Stage Lung Cancer Dx
• 5.40. Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics
• 5.41. Grail Gets Approval for Galleri Multicancer Test
• 5.42. Finnish Firms to Form Point-of-Care Testing Firm
• 5.43. Datar Cancer Genetics Expands to Dx and Screening
• 5.44. HTG Molecular Diagnostics: HTG Transcriptome Panel
• 5.45. PacBio's Omniome Acquisition Shortens Path to Clinical
• 5.46. Invitae to Acquire Genosity for $200M
• 5.47. Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
• 5.48. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
• 5.49. Natera Revenues Grow 35 Percent
• 5.50. AnchorDx Closes $40M Financing Round
• 5.51. Exact Sciences Strategy for End-to-End Cancer Testing
• 5.52. Genomics England: Whole Genome Sequencing for Cancer Patients to Launch

6. Profiles of Key MDx Companies

• 6.1. 10x Genomics, Inc.
• 6.2. Abbott Laboratories
• 6.3. AccuraGen Inc.
• 6.4. Acuamark Diagnostics
• 6.5. Adaptive Biotechnologies
• 6.6. Admera Health, LLC
• 6.7. Aethlon Medical
• 6.8. Agilent
• 6.9. Amoy Diagnostics Co., Ltd.
• 6.10. Anchor Dx
• 6.11. ANGLE plc
• 6.12. ARUP Laboratories
• 6.13. AVIVA Systems Biology
• 6.14. Baylor Miraca Genetics Laboratories
• 6.15. Beckman Coulter Diagnostics (Danaher)
• 6.16. Becton, Dickinson and Company
• 6.17. BGI Genomics Co. Ltd
• 6.18. BillionToOne
• 6.19. Bioarray Genetics
• 6.20. Biocartis
• 6.21. Biocept, Inc.
• 6.22. Biodesix Inc.
• 6.23. BioFluidica
• 6.24. BioGenex
• 6.25. BioIVT
• 6.26. Biolidics Ltd
• 6.27. bioMerieux Diagnostics
• 6.28. Bioneer Corporation
• 6.29. Bio-Rad Laboratories, Inc
• 6.30. Bio-Reference Laboratories
• 6.31. Bio-Techne
• 6.32. Bioview
• 6.33. Bristol-Myers Squibb
• 6.34. Burning Rock
• 6.35. C2i Genomics
• 6.36. Cardiff Oncology
• 6.37. Caris Molecular Diagnostics
• 6.38. Castle Biosciences, Inc.
• 6.39. Celemics
• 6.40. CellCarta
• 6.41. CellMax Life
• 6.42. Cepheid (Danaher)
• 6.43. Charles River Laboratories
• 6.44. Circulogene
• 6.45. Cizzle Biotech
• 6.46. Clearbridge Biomedics
• 6.47. Clinical Genomics
• 6.48. Cytolumina Technologies Corp.
• 6.49. Datar Cancer Genetics Limited
• 6.50. Diagnologix LLC
• 6.51. Diasorin S.p.A.
• 6.52. Dxcover
• 6.53. Element Biosciences
• 6.54. Enzo Biochem
• 6.55. Epic Sciences
• 6.56. Epigenomics AG
• 6.57. Erythra
• 6.58. Eurofins Scientific
• 6.59. Exact Sciences
• 6.60. Fabric Genomics
• 6.61. Fluxion Biosciences (Cell Microsystems)
• 6.62. Freenome
• 6.63. FUJIFILM Wako Diagnostics
• 6.64. Fujirebio
• 6.65. Fulgent Genetics
• 6.66. Fyr Diagnostics
• 6.67. GeneDx Holdings
• 6.68. GeneFirst Ltd.
• 6.69. Genetron Holdings
• 6.70. GenomOncology
• 6.71. GILUPI Nanomedizin
• 6.72. Guardant Health
• 6.73. HansaBiomed
• 6.74. HTG Molecular Diagnostics
• 6.75. iCellate
• 6.76. ICON PLC
• 6.77. Illumina
• 6.78. Incell Dx
• 6.79. Inivata
• 6.80. INOVIQ
• 6.81. Invitae Corporation
• 6.82. Invivogen
• 6.83. Invivoscribe
• 6.84. J&J Innovative Medicine
• 6.85. Lucence Health
• 6.86. Lucid Diagnostics
• 6.87. Lunglife AI Inc
• 6.88. MDNA Life SCIENCES, Inc.
• 6.89. MDx Health
• 6.90. Menarini Silicon Biosystems
• 6.91. Mesa Laboratories, Inc.
• 6.92. Metabiomics Corp
• 6.93. Millipore Sigma
• 6.94. Miltenyi Biotec
• 6.95. miR Scientific
• 6.96. Myriad Genetics
• 6.97. Nanostring
• 6.98. NantHealth, Inc.
• 6.99. Natera
• 6.100. NeoGenomics
• 6.101. NGeneBio
• 6.102. Novogene
• 6.103. Oncimmune
• 6.104. Oncocyte
• 6.105. OncoDNA
• 6.106. Oncohost
• 6.107. OraLiva
• 6.108. Oxford Nanopore Technologies
• 6.109. PamGene
• 6.110. Panagene
• 6.111. Personalis
• 6.112. Perthera
• 6.113. PGDx (Labcorp)
• 6.114. Precipio
• 6.115. PrecisionMed
• 6.116. Predicine
• 6.117. Predictive Oncology
• 6.118. Prenetics
• 6.119. Promega
• 6.120. Qiagen
• 6.121. QuidelOrtho
• 6.122. Rarecells SAS
• 6.123. RareCyte
• 6.124. Revvity
• 6.125. Roche Diagnostics
• 6.126. S2 Genomics
• 6.127. Screencell
• 6.128. Sherlock Biosciences
• 6.129. Siemens Healthineers
• 6.130. simfo GmbH
• 6.131. Singlera Genomics Inc.
• 6.132. Singular Genomics
• 6.133. Singulomics
• 6.134. SkylineDx
• 6.135. Standard BioTools
• 6.136. Stemcell Technologies
• 6.137. Stilla Technologies
• 6.138. Sysmex Inostics
• 6.139. Tempus Labs, Inc.
• 6.140. Thermo Fisher Scientific
• 6.141. Todos Medical
• 6.142. Ultima Genomics
• 6.143. Variantyx
• 6.144. Vela Diagnostics
• 6.145. Veracyte
• 6.146. VolitionRX
• 6.147. Vortex Biosciences
• 6.148. Zhejiang Orient Gene Biotech

7. The Global Market for MDx Cancer

• 7.1. MDx Cancer - Global Market Overview by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Cancer Type - Overview
  • 7.2.1. Table - Global Market by Cancer Type
  • 7.2.2. Chart - Global Market by Cancer Type - Base/Final Comparison
  • 7.2.3. Chart - Global Market by Cancer Type - Base Year
  • 7.2.4. Chart - Global Market by Cancer Type -Final Year
  • 7.2.5. Chart - Global Market by Cancer Type - Share by Year
  • 7.2.6. Chart - Global Market by Cancer Type - Segment Growth
• 7.3. Global Market by Product Type - Overview
  • 7.3.1. Table - Global Market by Product Type
  • 7.3.2. Chart - Global Market by Product Type - Base/Final Comparison
  • 7.3.3. Chart - Global Market by Product Type - Base Year
  • 7.3.4. Chart - Global Market by Product Type -Final Year
  • 7.3.5. Chart - Global Market by Product Type - Share by Year
  • 7.3.6. Chart - Global Market by Product Type - Segment Growth
• 7.4. Global Market by Place - Overview
  • 7.4.1. Table - Global Market by Place
  • 7.4.2. Chart - Global Market by Place - Base/Final Comparison
  • 7.4.3. Chart - Global Market by Place - Base Year
  • 7.4.4. Chart - Global Market by Place -Final Year
  • 7.4.5. Chart - Global Market by Place - Share by Year
  • 7.4.6. Chart - Global Market by Place - Segment Growth

8. Global Market by Cancer Type

• 8.1. MDx Breast Cancer
  • 8.1.1. Table Breast Cancer Testing - by Country
  • 8.1.2. Chart - Breast Cancer Testing Growth
• 8.2. MDx Colorectal Cancer
  • 8.2.1. Table Colorectal Cancer Testing - by Country
  • 8.2.2. Chart - Colorectal Cancer Testing Growth
• 8.3. MDx Cervical Cancer
  • 8.3.1. Table Cervical Cancer Testing - by Country
  • 8.3.2. Chart - Cervical Cancer Testing Growth
• 8.4. MDx Lung Cancer
  • 8.4.1. Table Lung Cancer Testing - by Country
  • 8.4.2. Chart - Lung Cancer Testing Growth
• 8.5. MDx Prostate
  • 8.5.1. Table Prostate Testing - by Country
  • 8.5.2. Chart - Prostate Testing Growth
• 8.6. MDx Melanoma Cancer
  • 8.6.1. Table Melanoma Cancer Testing - by Country
  • 8.6.2. Chart - Melanoma Cancer Testing Growth
• 8.7. MDx Blood
  • 8.7.1. Table Blood Testing - by Country
  • 8.7.2. Chart - Blood Testing Growth
• 8.8. MDx Companion Dx Development
  • 8.8.1. Table Companion Dx Development - by Country
  • 8.8.2. Chart - Companion Dx Development Growth
• 8.9. MDx Other Cancer
  • 8.9.1. Table Other Cancer Testing - by Country
  • 8.9.2. Chart - Other Cancer Testing Growth

9. Global Market by Product Type

• 9.1. MDx Instruments
  • 9.1.1. Table Instruments - by Country
  • 9.1.2. Chart - Instruments Growth
• 9.2. MDx Reagents
  • 9.2.1. Table Reagents - by Country
  • 9.2.2. Chart - Reagents Growth
• 9.3. MDx Software and Services
  • 9.3.1. Table Software and Services - by Country
  • 9.3.2. Chart - Software and Services Growth

10. Global Market by Place

• 10.1. MDx Clinical Laboratory
  • 10.1.1. Table Clinical Laboratory - by Country
  • 10.1.2. Chart - Clinical Laboratory Growth
• 10.2. MDx Pharmaceutical
  • 10.2.1. Table Pharmaceutical - by Country
  • 10.2.2. Chart - Pharmaceutical Growth
• 10.3. MDx Research
  • 10.3.1. Table Research - by Country
  • 10.3.2. Chart - Research Growth

11. Cancer Treatment and Trials

• 11.1. FDA Approvals by Year and Application
• 11.2. Clinical Trials Starts
• 11.3. Prevalence of Cancer Treatments

12. Appendices

• 12.1. United States Medicare System: Clinical Laboratory Fees Schedule
• 12.2. The Most Used IVD Assays
• 12.3. The Highest Grossing Assays
• 12.4. FDA Approved Human Genetic Tests
• 12.5. FDA Approved Pharmacogenomics Tests